Jim Simons’s Phathom Pharmaceuticals PHAT Stock Holding History

Jim Simons’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.4M	Buy	+305,800	New	+$3.86M	0.01%	1591
2024 Q1	–	Sell	-65,600	Closed	-$599K	–	3984
2023 Q4	$599K	Buy	+65,600	New	+$565K	﹤0.01%	2704
2023 Q3	–	Sell	-10,000	Closed	-$143K	–	3991
2023 Q2	$143K	Buy	+10,000	New	+$115K	﹤0.01%	3381
2022 Q3	–	Sell	-24,000	Closed	-$203K	–	4328
2022 Q2	$203K	Buy	+24,000	New	+$247K	﹤0.01%	3645
2021 Q2	–	Sell	-11,300	Closed	-$424K	–	3700
2021 Q1	$424K	Buy	+11,300	New	+$473K	﹤0.01%	2974

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Jim Simons's PHAT Position: Q1 2026 in Review

Jim Simons opened a new position in Phathom Pharmaceuticals (PHAT) in Q1 2026: 305,800 shares worth $3.4M. The stake represents 0.01% of the portfolio and ranks #1591 among its holdings. This is a return to the name: Jim Simons previously reported a position in PHAT as recently as Q4 2023.

Jim Simons first reported a position in PHAT in Q1 2021 and has held it in 5 quarters since. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

Jim Simons held 305,800 shares of Phathom Pharmaceuticals worth $3.4M as of Q1 2026.
Phathom Pharmaceuticals was a new Jim Simons position in Q1 2026.
Phathom Pharmaceuticals made up 0.01% of Jim Simons's portfolio in Q1 2026, its #1591 holding.
Jim Simons first reported a position in Phathom Pharmaceuticals in Q1 2021 and has held it in 5 quarters since.
174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.